Two powerhouses in the IT healthcare industry, GE Medical Systems Information Technologies and Qwest Communications International, have struck an exclusive, multiyear technology agreement to provide clinicians at healthcare systems with secure, reliable
Two powerhouses in the IT healthcare industry, GE Medical Systems Information Technologies and Qwest Communications International, have struck an exclusive, multiyear technology agreement to provide clinicians at healthcare systems with secure, reliable access to clinical information. GE and Qwest will offer a robust application service provider model that enables hospitals across the country to electronically store and retrieve medical images from remote sites. GE will offer ASP services to hospitals and healthcare systems; Qwest will store and manage the medical data. The companies estimate that the service will generate more than $250 million in top-line revenue. GE introduced its ASP last year using traditional long distance telephone networks. The company has since contracted to provide radiology and cardiology ASP services to more than 50 healthcare sites in the U.S.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.